---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-013021"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T04:33:02.762294+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# bioAffinity receives Nasdaq delisting notice; equity of $1.44M below $2.5M minimum

## Summary
- Stockholders' equity was $1,439,404 as of March 31, 2025, well below the $2,500,000 minimum.
- Company must submit a compliance plan by July 11, 2025 (45 days) to regain compliance.
- If plan accepted, Nasdaq may grant up to 180-day extension from May 27, 2025.
- Trading continues on Nasdaq Capital Market under BIAF and BIAFW symbols pending resolution.
- This notice is separate from prior bid price deficiency notice received February 7, 2025.

## SEC filing metadata
- accession: 0001641172-25-013021
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000164117225013021/0001641172-25-013021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000164117225013021/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-013021
- JSON: https://secwatch.observer/filing/0001641172-25-013021.json
- Plain text: https://secwatch.observer/filing/0001641172-25-013021.txt

## Key facts
- Listing & Compliance Notices
  bioAffinity Technologies, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: May 27, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”) because the stockholders’ equity of the Company of $1,439,404 as of March 31, 2025, as reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2025, was below the minimum requirement of $2,500,000. As of the date of this Current Report on Form 8-K, the Company does not have a market value of listed secu
  evidence_url: https://www.sec.gov/Archives/edgar/data/1712762/000164117225013021/0001641172-25-013021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.